Lipid Nanoparticles Immunogenicity and Toxicity Hyatt Regency Boston, Boston

Enhance Your Prediction of PKPD, Accurate Dosing Regime and Immuno-Modulation of LNP for Long-Term Patient Safety and Potency
Following the success of LNP-mRNA vaccines, we have seen an influx of novel types of lipids based nanocarriers over the last 12 months, progress has been made to minimize immuno-toxicity challenges – from maximizing therapeutic window to fine-tuning the immune response.

The highly anticipated Lipid Nanoparticle Immunogenicity and Toxicity Summit takes place this December to unite 80+ senior leaders as the definitive meeting for clinical pharmacology, immunogenicity, bioanalytical development leaders to stay at the forefront, arming you with practical takeaways and lessons learned.

Across 3 days, we will delve into:

HW220702 LNP Immunogenicity and Toxicity logo Favicon
Immunomodulation strategies to increase the therapeutic window

HW220702 LNP Immunogenicity and Toxicity logo Favicon
Translatable preclinical models to revolutionize clinical relevancy

HW220702 LNP Immunogenicity and Toxicity logo Favicon
Dosing considerations dependent on your disease indication, route of administration and patient group for improved safety

And much more!

Hear the latest insights and case studies to optimize your prediction of PKPD, accurate dosing regime and immuno-modulation of LNP for long-term patient safety and potency.

Across 3 days, with over 6 hours of networking, this is your must-attend summit in 2022, to join the likes of AstraZeneca, Bristol Myers Squibb, NanoVation Therapeutics, Vertex Pharmaceuticals to lay the foundation for robust immunotoxicity protocols, propelling your novel pipeline growth.